Millions of people in the U.S. and around the world experience psoriasis and psoriatic arthritis, and there is no cure, yet.
Psoriasis by the Numbers
- According to current studies, more than 8 million Americans have psoriasis. 
- 125 million people worldwide — 2 to 3 percent of the total population — have psoriasis, according to the World Psoriasis Day consortium.
- An estimated 30 percent of people with psoriasis also develop psoriatic arthritis. 
- Psoriasis prevalence in African Americans is 1.5 percent compared to 3.6 percent of Caucasians. 
- Psoriasis is likely to be underdiagnosed among African-Americans and other individuals with skin of color due to differences in clinical presentation. 
Quality of Life
- Psoriasis is not a cosmetic problem. Nearly 60 percent of people with psoriasis reported their disease to be a large problem in their everyday life. 
- Nearly 40 percent with psoriatic arthritis reported their disease to be a large problem in everyday life. 
- Patients with moderate to severe psoriasis experienced a greater negative impact on their quality of life. 
- Psoriasis has a greater impact on the quality of life in women and younger patients. 
- Individuals with psoriasis experience higher rates of many comorbidities, including cardiovascular disease, heart attack , stroke , metabolic syndrome , and depression , among others.
Age of Onset
- Psoriasis can appear at any age, but often has two peaks of onset. The first is between 20 – 30 years of age and the second between 50 – 60 years of age. 
- Psoriatic arthritis usually develops between the ages of 30 and 50, but can develop at any age.
- The National Psoriasis Foundation defines mild psoriasis as affecting less than 3 percent of the body; 3 percent to 10 percent is considered moderate; more than 10 percent is considered severe. For most individuals, your hand is about the same as 1 percent of the skin surface.
- However, the severity of psoriasis is also measured by how psoriasis affects a person's quality of life. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. 
- Patients with psoriasis incur annual health care costs that are significantly greater than those of the general population and may amount to $135 billion annually (2013, U.S. $). 
- In the United States, the economic burden of psoriasis is substantial because this disease results in considerable negative physical, psychiatric, and social consequences. 
 Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. Published online June 30, 2021. doi:10.1001/jamadermatol.2021.2007
 Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology. 2013;69(5):729-735.
 Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16-24.
 Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
 Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005;53(4):573.
 Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004;51(5):704-708.
 Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of Myocardial Infarction in Patients With Psoriasis. JAMA. 2006;296(14):1735-1741.
 Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. The Journal of investigative dermatology. 2009;129(10):2411-2418.
 Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. Journal of the American Academy of Dermatology. 2013;68(4):654-662.
 Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. The Journal of investigative dermatology. 2014;134(6):1542-1551.
 Armstrong AW. Psoriasis. JAMA dermatology. 2017;153(9):956-956.
 Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. American journal of preventive medicine. 2014;47(1):37-45.
 Brezinski EA, Dhillon JS, Armstrong AW. Economic Burden of Psoriasis in the United States: A Systematic Review. JAMA dermatology. 2015;151(6):651-658.
 Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatric dermatology. 2013;30(4):424-428.
 Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R. The epidemiology of childhood psoriasis: a scoping review. The British journal of dermatology. 2016;174(6):1242-1257.
Last updated on 12/21/2022 by the National Psoriasis Foundation.